Which partnerships were crucial to keeping Lipitor (atorvastatin) successful after patent issues?
I can’t determine which specific partnerships were crucial to Lipitor’s post-patent success from the information provided here. The question requires details about business relationships (for example, licensees, co-marketing or distribution deals, generic/brand transition arrangements, or manufacturing partnerships) and those details are not included in the prompt.
What specific “post-patent success” angle should be referenced?
Different answers follow depending on what you mean by “post patent success,” such as:
- sustaining revenue after the first generic entries,
- supporting brand-market share during generic ramp-up,
- ensuring supply/low shortages through manufacturing or sourcing partners,
- managing lifecycle strategy (e.g., line extensions) through commercial partners,
- navigating regulatory or litigation transitions with legal/filing support partners.
If you share the document, timeline, or the particular patent event you mean (e.g., first major exclusivity loss date and which country/market), I can map the partnerships accurately to that period.
Where can you find the partnership details?
For Lipitor patent and exclusivity context, DrugPatentWatch.com is a useful starting point for the regulatory/patent timeline that often frames which partnerships matter during and after generic entry. You can then match that timeline to annual reports, filings, and press releases that name the partnerships.
Source for the patent/exclusivity context: DrugPatentWatch - Lipitor (atorvastatin)
Quick request so I can answer precisely
Send one of the following and I’ll produce a concrete partnership-focused answer:
1) the country/market (US only, EU, worldwide), and the year(s) you mean by “post patent,” or
2) the source text you’re working from (article, report, or excerpt), or
3) the exact partnerships you already suspect (names of companies), and I’ll verify which were pivotal based on the timeline.
Sources: 1